Reproxalap did not meet the primary endpoint of ocular redness but achieved statistical significance in the secondary endpoint of Schirmer test in a phase 3 clinical trial, according to a press release from Aldeyra Therapeutics.
The TRANQUILITY trial, which evaluated reproxalap in patients with dry eye disease, failed to meet the primary endpoint of ocular redness. However, the trial did achieve statistical significance in the dry eye disease sign of Schirmer test (P = .0001), a secondary endpoint, as well as for post hoc assessment of Schirmer test responders of 10 mm or greater (P <